UnitedHealthcare - 2014 to Present
Skyrizi (150 MG Dose) (risankizumab-rzaa)
Drugs for the Skin : Drugs for the Skin
  • Psoriasis (PsO):
    Duration: 12 Month(s)
    Documented Diagnosis: Yes
    Medical Test Required: No
    Reauthorization Required: Yes
    Duration of Reauthorization: = 24 month(s)
    TB Test required: No
    History of Plaque Psoriasis: N/A
    Overall % of Body Surface For Initiation: N/A
    Overall % of Body Surface For Initiation With Sensitive Areas: N/A
    Psoriasis Classification: Moderate-Severe
    Sensitive Area BSA Percent override: No

  • Prior Authorization: Psoriasis (PsO):
    Documented Diagnosis: Yes
    Duration: 12 Month(s)
    Reauthorization Required: Yes